

Josã© Marã-a Pego-Reigosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8837831/publications.pdf>

Version: 2024-02-01

82
papers

4,384
citations

185998

28
h-index

114278

63
g-index

86
all docs

86
docs citations

86
times ranked

4537
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1529-1550. | 1.1 | 19 |
| 2 | Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology. <i>BMC Health Services Research</i> , 2022, 22, 60. | 0.9 | 5 |
| 3 | Central Role of Semaphorin 3B in a Serum-Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 972-983. | 2.9 | 9 |
| 4 | Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151946. | 1.6 | 4 |
| 5 | Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. <i>Cells</i> , 2022, 11, 515. | 1.8 | 15 |
| 6 | Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 12. | 1.0 | 2 |
| 7 | Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. <i>Rheumatology</i> , 2022, 62, 217-224. | 0.9 | 1 |
| 8 | Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*. <i>ReumatologÃa ClÃnica (English)</i> Tj ETQq0 0.0,rgBT /Overlock 10 | 0.2 | 16 |
| 9 | Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, e47-e50. | 0.5 | 4 |
| 10 | Comorbidities (excluding lymphoma) in SjÃgren's syndrome. <i>Rheumatology</i> , 2021, 60, 2075-2084. | 0.9 | 30 |
| 11 | Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, 17, 245-249. | 0.2 | 0 |
| 12 | The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 60-72. | 0.9 | 42 |
| 13 | Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803. | 0.9 | 23 |
| 14 | OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, e455. | 0.9 | 0 |
| 15 | Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1263. | 1.8 | 16 |
| 16 | European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781. | 0.5 | 37 |
| 17 | Myo-Spain: Registro de pacientes con miopatÃa inflamatoria idiopÃtica de EspaÃa. <i>MetodologÃa. ReumatologÃa ClÃnica</i> , 2021, , . | 0.2 | 0 |
| 18 | What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506. | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336. | 0.9 | 4 |
| 20 | Aportaciones del registro de lupus de la Sociedad EspaÃ±ola de ReumatologÃ­a (RELESSER) al conocimiento del lupus eritematoso sistÃ©mico en EspaÃ±a. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, 17, 245-249. | 0.2 | 0 |
| 21 | Prevalencia de artrosis sintomÃ¡tica en EspaÃ±a: Estudio EPISER2016. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, 17, 461-470. | 0.2 | 20 |
| 22 | Distinctive CD26 Expression on CD4 T-Cell Subsets. <i>Biomolecules</i> , 2021, 11, 1446. | 1.8 | 3 |
| 23 | Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply. <i>Rheumatology</i> , 2021, 60, e120-e121. | 0.9 | 1 |
| 24 | Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables. <i>Rheumatology International</i> , 2021, , 1. | 1.5 | 0 |
| 25 | Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 736-745. | 0.4 | 0 |
| 26 | Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. <i>RMD Open</i> , 2021, 7, e001925. | 1.8 | 8 |
| 27 | Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. <i>Journal of Rheumatology</i> , 2020, 47, 234-240. | 1.0 | 19 |
| 28 | Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 216-224. | 1.5 | 11 |
| 29 | Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020, 59, 2043-2051. | 0.9 | 10 |
| 30 | Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6965. | 1.8 | 16 |
| 31 | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7100. | 1.8 | 39 |
| 32 | Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339. | 0.5 | 35 |
| 33 | Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565. | 0.8 | 19 |
| 34 | Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9544. | 1.8 | 8 |
| 35 | Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 657-662. | 1.6 | 5 |
| 36 | Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary SjÃ¶rgren syndrome. <i>Rheumatology International</i> , 2020, 40, 1259-1265. | 1.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990. | 0.5 | 66 |
| 38 | Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?. <i>Rheumatology</i> , 2020, 59, 2556-2562. | 0.9 | 32 |
| 39 | Desarrollo de una aplicaci3n para tel3fonos m3viles (app) basada en la colaboraci3n Sociedad Espaola de Reumatolog3a/Sociedad Espaola de Medicina de Familia y Comunitaria para derivaci3n de enfermedades autoinmunes sist3micas. <i>Reumatolog3a Cl3nica</i> , 2020, 16, 373-377. | 0.2 | 7 |
| 40 | Biological therapy safety in chronic inflammatory arthropathy patients. <i>European Journal of Rheumatology</i> , 2020, 7, 53-59. | 1.3 | 0 |
| 41 | Valoraci3n del riesgo de fractura en poblaci3n general en Espa3a mediante el algoritmo FRAX3: Estudio EPISER2016. <i>Medicina Cl3nica</i> , 2020, 154, 163-170. | 0.3 | 1 |
| 42 | 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159. | 0.5 | 759 |
| 43 | 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412. | 2.9 | 1,098 |
| 44 | How to investigate: Suspected systemic rheumatic diseases in patients presenting with muscle complaints. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101437. | 1.4 | 3 |
| 45 | Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , 2019, 9, e028697. | 0.8 | 15 |
| 46 | Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1025-1029. | 1.6 | 14 |
| 47 | Prevalencia de enfermedades reum3ticas en poblaci3n adulta en Espa3a (estudio EPISER 2016). <i>Objetivos y metodolog3a</i> . <i>Reumatolog3a Cl3nica</i> , 2019, 15, 90-96. | 0.2 | 63 |
| 48 | Content analysis of Twitter in relation to biological treatments for chronic inflammatory arthropathies: an exploratory study. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 124-128. | 0.5 | 6 |
| 49 | Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>Reumatolog3a Cl3nica</i> , 2019, 15, 34-42. | 0.2 | 6 |
| 50 | Adherence to biological therapies in patients with chronic inflammatory arthropathies. <i>Farmacia Hospitalaria</i> , 2019, 43, 134-139. | 0.6 | 3 |
| 51 | Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 280. | 1.6 | 40 |
| 52 | Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 100. | 1.6 | 102 |
| 53 | Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45. | 1.6 | 117 |
| 54 | Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. <i>Clinical Biochemistry</i> , 2017, 50, 903-910. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 38-45. | 1.5 | 27 |
| 56 | Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1047-1055. | 0.4 | 14 |
| 57 | Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). <i>Medicine (United States)</i> , 2016, 95, e2891. | 0.4 | 55 |
| 58 | Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250. | 0.9 | 28 |
| 59 | Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14. | 0.1 | 7 |
| 60 | Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183. | 0.4 | 96 |
| 61 | CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0131992. | 1.1 | 19 |
| 62 | Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729. | 0.8 | 20 |
| 63 | Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 1180-1185. | 1.5 | 125 |
| 64 | Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267. | 0.4 | 48 |
| 65 | Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. <i>Rheumatology International</i> , 2015, 35, 1447-1459. | 1.5 | 29 |
| 66 | Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2015, 35, 17-26. | 1.5 | 100 |
| 67 | Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. <i>Reumatología Clínica</i> , 2014, 10, 17-24. | 0.2 | 55 |
| 68 | Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185. | 1.6 | 101 |
| 69 | Biological therapy for systemic vasculitis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 542-557. | 1.6 | 41 |
| 70 | National Registry of Patients With Systemic Lupus Erythematosus of the Spanish Society of Rheumatology: Objectives and Methodology. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 17-24. | 0.2 | 11 |
| 71 | Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. <i>Reumatología Clínica</i> , 2013, 9, 281-296. | 0.2 | 31 |
| 72 | SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 281-296. | 0.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 1775-1785. | 1.5 | 50 |
| 74 | Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 256-264. | 1.6 | 244 |
| 75 | Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , 2010, 49, 691-696. | 0.9 | 29 |
| 76 | Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971. | 0.9 | 94 |
| 77 | Respiratory manifestations of systemic lupus erythematosus: old and new concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 469-480. | 1.4 | 117 |
| 78 | Autoimmune diseases. <i>Medicine</i> , 2008, 36, 279-283. | 0.2 | 0 |
| 79 | Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 48, 573-575. | 0.9 | 23 |
| 80 | Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. <i>Rheumatology</i> , 2008, 47, 1498-1502. | 0.9 | 132 |
| 81 | Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 31-41. | 1.9 | 14 |
| 82 | Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: A prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. <i>Arthritis and Rheumatism</i> , 2005, 53, 931-938. | 6.7 | 52 |